Page 114 - GPD-3-3

Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM

8. Gandhi P, Shrivastava R, Garg N, Sorte SK. Novel molecular cytokine-induced neutrophil chemoattractant-1 synthesized
panel for evaluating systemic inflammation and survival in response to inflammatory stimulation in rats. Lab Anim
in therapy naïve glioma patients. World J Clin Oncol. Res. 2018;34(2):80-83.
2021;12(10):947-959.
doi: 10.5625/lar.2018.34.2.80
doi: 10.5306/wjco.v12.i10.947
20. Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory
9. Gulhar R, Ashraf MA, Jialal I. Physiology, acute phase biomarkers are associated with total brain volume:
reactants. In: StatPearls. Treasure Island, FL: StatPearls The Framingham Heart Study. Neurology. 2007;68(13):
Publishing; 2024. 1032-1038.
10. Kureshi SA, Hofman FM, Schneider JH, Chin LS, Apuzzo ML, doi: 10.1212/01.wnl.0000257815.20548.df
Hinton DR. Cytokine expression in radiation-induced
delayed cerebral injury. Neurosurgery. 1994;35(5):822-829; 21. Garrett C, Becker TM, Lynch D, et al. Comparison of
discussion 829-830. neutrophil to lymphocyte ratio and prognostic nutritional
index with other clinical and molecular biomarkers for
doi: 10.1227/00006123-199411000-00004 prediction of glioblastoma multiforme outcome. PLoS One.
11. Mostafa H, Pala A, Högel J, et al. Immune phenotypes 2021;16(6):e0252614.
predict survival in patients with glioblastoma multiforme. doi: 10.1371/journal.pone.0252614
J Hematol Oncol. 2016;9(1):77.
22. Nijaguna MB, Patil V, Hegde AS, et al. An eighteen serum
doi: 10.1186/s13045-016-0272-3 cytokine signature for discriminating glioma from normal
12. Demirci U, Yaman M, Buyukberber S, et al. Prognostic healthy individuals. PLoS One. 2015;10(9):e0137524.
importance of markers for inflammation, angiogenesis and doi: 10.1371/journal.pone.0137524
apoptosis in high grade glial tumors during temozolomide
and radiotherapy. Int Immunopharmacol. 2012;14(4): 23. Brommeland T, Rosengren L, Fridlund S, Hennig R,
546-549. Isaksen V. Serum levels of glial fibrillary acidic protein
correlate to tumour volume of high-grade gliomas. Acta
doi: 10.1016/j.intimp.2012.08.007
Neurol Scand. 2007;116(6):380-384.
13. Sultana N, Sun C, Katsube T, Wang B. Biomarkers of brain doi: 10.1111/j.1600-0404.2007.00889.x
damage induced by radiotherapy. Dose Response. 2020;18(3).
24. van Linde ME, van der Mijn JC, Pham TV, et al. Evaluation
doi: 10.1177/1559325820938279
of potential circulating biomarkers for prediction of
14. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. response to chemoradiation in patients with glioblastoma.
STRING: A database of predicted functional associations J Neurooncol. 2016;129(2):221-230.
between proteins. Nucleic Acids Res. 2003;31(1):258-261.
doi: 10.1007/s11060-016-2178-x
doi: 10.1093/nar/gkg034
25. Jain S, Gautam V, Naseem S. Acute-phase proteins: As
15. Goutnik M, Lucke-Wold B. Commentary: Evaluating diagnostic tool. J Pharm Bioallied Sci. 2011;3(1):118-127.
potential glioma serum biomarkers, with future applications.
World J Clin Oncol. 2022;13(5):412-416. doi: 10.4103/0975-7406.76489
doi: 10.5306/wjco.v13.i5.412 26. Luan YY, Yao YM. The clinical significance and potential
role of C-reactive protein in chronic inflammatory and
16. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. neurodegenerative diseases. Front Immunol. 2018;9:1302.
Vorasidenib in IDH1- or IDH2-mutant low-grade glioma.
N Engl J Med. 2023;389:589-601. doi: 10.3389/fimmu.2018.01302
doi: 10.1056/NEJMoa2304194 27. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in
human proteomics at high scale with the SOMAscan
17. Niehues T. C-reactive protein and other biomarkers-the proteomics platform. N Biotechnol. 2012;29(5):543-549.
sense and non-sense of using inflammation biomarkers for
the diagnosis of severe bacterial infection. LymphoSign J. doi: 10.1016/j.nbt.2011.11.016
2018;5(2):35-47. 28. Tuerk C, Gold L. Systematic evolution of ligands by
doi: 10.14785/lymphosign-2018-0001 exponential enrichment: RNA ligands to bacteriophage T4
DNA polymerase. Science. 1990;249(4968):505-510.
18. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP
as an emerging biomarker in brain and spinal cord disorders. doi: 10.1126/science.2200121
Nat Rev Neurol. 2022;18(3):158-172. 29. Candia J, Cheung F, Kotliarov Y, et al. Assessment of
doi: 10.1038/s41582-021-00616-3 variability in the SOMAscan assay. Sci Rep. 2017;7(1):14248.
19. Kuribayashi T. Elimination half-lives of interleukin-6 and doi: 10.1038/s41598-017-14755-5

Volume 3 Issue 3 (2024) 14 doi: 10.36922/gpd.3580